This orally administered multi-targeted tyrosine kinase inhibitor exerts its anti-tumor effects by inhibiting the tyrosine kinase activity of FGFR1-4, thereby blocking FGFR signaling and suppressing tumor cell proliferation. Here, FGFR1 is linked to neoplasm.